Ensysce Biosciences Inc (ENSC)
$0.43
$-0.01
(-1.17%)
As on 04-Sep-2026 13:35EDT
Market cap
$8 Mln
Revenue (TTM)
$5 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-7 Mln
-
ROE
-13 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2.1
-
Face value
--
-
Shares outstanding
19,456,794
7 Years Aggregate
CFO
$-28.65 Mln
EBITDA
$-60.71 Mln
Net Profit
$-62.09 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ensysce Biosciences Inc (ENSC)
| -52.7 | 55.2 | 64.1 | -80.0 | -74.7 | -87.1 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ensysce Biosciences Inc (ENSC)
| -88.7 | -48.5 | -88.2 | -99.2 | -62.2 | 19.3 | 6.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ensysce Biosciences Inc (ENSC)
|
0.4 | 7.8 | 4.5 | -12.6 | -223.2 | -- | -- | 0.9 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Ensysce Biosciences Inc (ENSC)
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP)... platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California. Read more
-
President, CEO & Director
Dr. D. Lynn Kirkpatrick Ph.D.
-
President, CEO & Director
Dr. D. Lynn Kirkpatrick Ph.D.
-
Headquarters
La Jolla, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ensysce Biosciences Inc (ENSC)
What is the current share price of Ensysce Biosciences Inc (ENSC) Today?
The share price of Ensysce Biosciences Inc (ENSC) is $0.43 (NASDAQ) as of 04-Sep-2026 13:35 EDT. Ensysce Biosciences Inc (ENSC) has given a return of -74.75% in the last 3 years.
What is the current PB & PE ratio of Ensysce Biosciences Inc (ENSC)?
Since, TTM earnings of Ensysce Biosciences Inc (ENSC) is negative, P/E ratio is not available.
The P/B ratio of Ensysce Biosciences Inc (ENSC) is 0.86 times as on 28-Aug-2026, a 83 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-2.31 |
7.32 |
2024 |
-1.25 |
2.70 |
2023 |
-0.23 |
-7.43 |
2022 |
-0.01 |
-0.06 |
2021 |
-0.02 |
-0.06 |
What is the 52 Week High and Low of Ensysce Biosciences Inc (ENSC)?
The 52-week high and low of Ensysce Biosciences Inc (ENSC) are Rs 2.75 and Rs 0.23 as of 05-Sep-2026.
What is the market cap of Ensysce Biosciences Inc (ENSC)?
Ensysce Biosciences Inc (ENSC) has a market capitalisation of $ 8 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ensysce Biosciences Inc (ENSC)?
Before investing in Ensysce Biosciences Inc (ENSC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.